Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Repertaxin in the Prevention of Primary Graft Dysfunction After Lung Transplantation

NCT00224406 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.

NCT NCT00224406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00224406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Repertaxin in the Prevention of Primary Graft Dysfunction After Lung Transplantation
Lead sponsor
Dompé Farmaceutici S.p.A
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2005
Completion date
September 13, 2007
Enrollment
114 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ischemia-reperfusion injury, lung transplantation